Wire · opportunities
First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The FDA has approved apitegromab (Isembyld), the first therapy targeting muscle loss in spinal muscular atrophy, which may improve motor function when used with other treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
You have new FDA-approved drug options to offer patients with spinal muscular atrophy, opening a route to improve motor outcomes alongside existing therapies. Prepare to engage clinicians focused on rare neuromuscular conditions as treatment standards evolve.
◆ Coverage
9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics